Key facts
- CATX - Perspective Therapeutics, Inc. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: +$42,241.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 17 Insiders of Perspective Therapeutics, Inc.
- Symbol
- CATX on NYSE
- Location
- Seattle, WA
Change
- Buy value: $42,241; sell value: $0.
- Net share flow: +20,498.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$42,241.
Buys
$42,241
Shares: 20,498
Insiders: 2
Sells
$0
Shares: 0
Insiders: 0
Net
+$42,241
Shares: +20,498
Insiders: 2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 20,498 | 0 | $42,241 | $0 | +$42,241 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Perspective Therapeutics, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10%+ Owner | $110,934,724 | Filing P/S | 06 Mar 2024 | ||
| Lori A. Woods | Director | $400,989 | Mixed | 02 Mar 2026 | ||
| Robert F. Williamson III | Director | $394,522 | +$19,946 | +5.3% | Mixed | 02 Mar 2026 |
| Johan M. Spoor | Chief Executive Officer, Director | $194,133 | Mixed | 02 Mar 2026 | ||
| Jonathan Robert Hunt | Chief Accounting Officer | $121,202 | +$22,295 | +23% | Filing P/S | 02 Mar 2026 |
| Juan Graham | Chief Financial Officer | $79,490 | Filing P/S | 28 Mar 2025 | ||
| Mark John Austin | VP Finance/Prin Fin&Acct Offic | $30,251 | Mixed | 17 Jul 2024 | ||
| Philip J. Vitale | Director | Mixed | 21 Jul 2022 | |||
| Alan Hoffmann | Director | Mixed | 21 Jul 2022 | |||
| William Cavanagh | Chief R&D Officer | Mixed | 21 Jul 2022 | |||
| Frank Morich | Director | Mixed | 02 Mar 2026 | |||
| Michael W. McCormick | Director | Mixed | 21 Feb 2023 | |||
| Jennifer Streeter | COO & VP of HR | Mixed | 12 Jun 2023 | |||
| Markus Puhlmann | Chief Medical Officer | Mixed | 02 Mar 2026 | |||
| Maria E. Martinez | Director | Mixed | 02 Mar 2026 | |||
| Joel Sendek | Chief Financial Officer | Mixed | 04 Sep 2025 | |||
| Heidi Henson | Director | Mixed | 02 Mar 2026 |
Top shareholders of Perspective Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP |
13D/G
13F
|
Company |
9.9%
|
11,939,753
|
$29,968,780 | $0 | 02 Feb 2026 | |
| TCG Crossover GP II, LLC |
13D/G
|
Chen Yu |
6.9%
|
7,915,567
|
$21,767,809 | $0 | 03 Feb 2026 | |
| Qatar Investment Authority |
13D/G
|
— |
6.2%
|
7,073,308
|
$19,451,597 | $0 | 04 Feb 2026 | |
| Avidity Partners Management LP |
13D/G
13F
|
Company |
5.3%
|
6,049,999
|
$29,523,995 | +$15,659,798 | 20 Feb 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
4.6%
from 13D/G
|
5,348,561
|
$22,303,498 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13D/G
13F
|
Company |
2.6%
|
2,959,296
|
$13,080,088 | -$6,641,479 | 31 Mar 2026 | |
| FMR LLC |
13F
13D/G
|
Company |
0.4%
from 13D/G
|
313,658
|
$1,307,954 | — | 31 Mar 2026 | |
| JANUS HENDERSON GROUP PLC |
13D/G
|
— |
0.02%
|
17,839
|
$43,349 | $0 | 31 Dec 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
7%
|
7,915,567
|
$33,007,914 | — | 31 Mar 2026 | |
| Opaleye Management Inc. |
13F
|
Company |
4.1%
|
4,675,000
|
$19,494,750 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.8%
|
4,378,956
|
$18,260,247 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
3.6%
|
4,046,640
|
$16,874,489 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.1%
|
3,566,504
|
$14,872,322 | — | 31 Mar 2026 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
2.8%
|
3,164,582
|
$13,196,307 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
2.8%
|
3,132,670
|
$13,063,234 | — | 31 Mar 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
2.6%
|
2,994,460
|
$12,486,898 | — | 31 Mar 2026 | |
| Spruce Street Capital LP |
13F
|
Company |
2.3%
|
2,627,107
|
$10,955,036 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
1,766,960
|
$7,370,455 | — | 31 Mar 2026 | |
| Patient Square Capital LP |
13F
|
Company |
1.4%
|
1,625,000
|
$6,776,250 | — | 31 Mar 2026 | |
| Nicholson Wealth Management Group, LLC |
13F
|
Company |
1.4%
|
1,618,993
|
$6,751,201 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.1%
|
1,241,816
|
$5,178,373 | — | 31 Mar 2026 | |
| Fan Yu |
13F
|
Individual |
0.93%
|
1,055,409
|
$4,401,056 | — | 31 Mar 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.88%
|
1,003,474
|
$4,184,487 | — | 31 Mar 2026 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.81%
|
926,557
|
$3,863,743 | — | 31 Mar 2026 | |
| Nuveen, LLC |
13F
|
Company |
0.8%
|
910,221
|
$3,795,621 | — | 31 Mar 2026 | |
| Hills Bank & Trust Co |
13F
|
Company |
0.77%
|
872,200
|
$3,637,074 | — | 31 Mar 2026 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.7%
|
791,555
|
$3,300,784 | — | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
0.66%
|
752,033
|
$3,135,978 | — | 31 Mar 2026 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.66%
|
749,335
|
$3,124,727 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.58%
|
661,318
|
$2,757,696 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.5%
|
566,676
|
$2,363,039 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.46%
|
528,928
|
$2,205,630 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.46%
|
520,905
|
$2,172,174 | — | 31 Mar 2026 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.4%
|
450,097
|
$1,876,905 | — | 31 Mar 2026 | |
| WealthPlan Investment Management, LLC |
13F
|
Company |
0.36%
|
404,071
|
$1,684,976 | — | 31 Mar 2026 | |
| Seven Fleet Capital Management LP |
13F
|
Company |
0.33%
|
379,082
|
$1,580,772 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.21%
|
241,924
|
$1,008,823 | — | 31 Mar 2026 | |
| Invesco Ltd. |
13F
|
Company |
0.2%
|
231,355
|
$964,750 | — | 31 Mar 2026 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.2%
|
222,142
|
$926,332 | — | 31 Mar 2026 | |
| CITIGROUP INC |
13F
|
Company |
0.19%
|
212,131
|
$884,586 | — | 31 Mar 2026 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.16%
|
186,630
|
$778,247 | — | 31 Mar 2026 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.16%
|
185,335
|
$772,845 | — | 31 Mar 2026 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.16%
|
183,342
|
$764,536 | — | 31 Mar 2026 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.15%
|
169,147
|
$705,343 | — | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.15%
|
168,223
|
$701,489 | — | 31 Mar 2026 | |
| Rothschild Wealth LLC |
13F
|
Company |
0.14%
|
164,821
|
$687,304 | — | 31 Mar 2026 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.1%
|
119,114
|
$496,705 | — | 31 Mar 2026 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.1%
|
117,051
|
$488,103 | — | 31 Mar 2026 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.1%
|
115,489
|
$481,589 | — | 31 Mar 2026 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
110,800
|
$462,036 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Perspective Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Maria E. Martinez | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Frank Morich | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Robert F. Williamson III | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Heidi Henson | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Lori A. Woods | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Johan M. Spoor | CATX | Stock option (right to buy) | Award | 735,000 | 735,000 | 02 Mar 2026 | Direct | |||
| Jonathan Robert Hunt | CATX | Stock option (right to buy) | Award | 90,000 | 90,000 | 02 Mar 2026 | Direct | |||
| Markus Puhlmann | CATX | Stock option (right to buy) | Award | 150,000 | 150,000 | 02 Mar 2026 | Direct | |||
| Jonathan Robert Hunt | CATX | Common Stock | Purchase | 22.5% | $22,295 | $2.03 | 11,000 | 59,800 | 13 Nov 2025 | Direct |
| Robert F. Williamson III | CATX | Common Stock | Purchase | 2595.1% | $19,946 | $2.10 | 9,498 | 9,864 | 12 Nov 2025 | RFW3 Revocable Trust |
| Joel Sendek | CATX | Stock option (right to buy) | Award | 600,000 | 600,000 | 04 Sep 2025 | Direct | |||
| Maria E. Martinez | CATX | Stock option (right to buy) | Award | 75,000 | 75,000 | 03 Sep 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.